Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology a...

Descripción completa

Detalles Bibliográficos
Autores: Bellet, Meritxell, Ahmad, Faten, Villanueva, Rafael, Valdivia, Carolina, Palomino-Doza, Julian, Ruiz, Ada, Gonzalez, Xavier, Adrover, Encarna, Azaro, Analia, Valls-Margarit, Maria, Parra, Josep Lluis, Aguilar, Juan, Vidal, Maria, Martin, Anastasi, Gavila, Joaquin, Escriva-de-Romani, Santiago, Perello Martorell, Antonia, Hernando, Cristina, Lahuerta, Ainhara, Zamora, Pilar, Reyes, Victoria, Alcalde, Maria, Masanas, Helena, Celiz, Pamela, Ruiz, Isabel, Gil, Miguel, Segui, Miguel Angel, de la Pena, Lorena
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/22805
Acceso en línea:https://hdl.handle.net/20.500.12105/22805
Access Level:acceso abierto
Palabra clave:CDK inhibitors
Palbociclib
Ribociclib
Breast cancer
Descripción
Sumario:Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.

Similares en LA Referencia